Alphatec Holdings (ATEC) Aktievy
Alphatec Holdings, Inc, ett medicintekniskt företag, designar, utvecklar och förbättrar teknologier för kirurgisk behandling av ryggradssjukdomar i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 4/6 |
| Framtida tillväxt | 4/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 2/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för ATEC från våra riskkontroller.
ATEC Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Alphatec Holdings, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$9.79 |
| 52 veckors högsta | US$23.29 |
| 52 veckors lägsta | US$6.82 |
| Beta | 0.86 |
| 1 månads förändring | 14.70% |
| 3 månaders förändring | 21.01% |
| 1 års förändring | -37.64% |
| 3 års förändring | -32.06% |
| 5 års förändring | -20.73% |
| Förändring sedan börsintroduktionen | -90.92% |
Senaste nyheter och uppdateringar
Seeking Alpha • Aug 07
Alphatec: Straightening Its Back
Summary Alphatec reports 15% revenue growth and improved operating leverage, with realistic break-even levels approaching despite ongoing net losses and dilution. Alphatec maintains $882 million in sales guidance and raises adjusted EBITDA guidance to $140 million, signaling confidence in margin improvements and operational progress. Leverage concerns are easing as free cash flow turns positive, dilution slows, and interest expenses decline, aided by strong EOS imaging technology growth. Trading at just over 2x sales, Alphatec offers speculative appeal given robust growth, margin gains, and a significant discount to peer multiples. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 05
ATEC: 2026 Revenue Mix Will Support Constructive Upside Case
Analysts have adjusted their price target on Alphatec Holdings from $24.00 to about $22.41. The change reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E estimates.Recent updates
Seeking Alpha • Aug 07
Alphatec: Straightening Its Back
Summary Alphatec reports 15% revenue growth and improved operating leverage, with realistic break-even levels approaching despite ongoing net losses and dilution. Alphatec maintains $882 million in sales guidance and raises adjusted EBITDA guidance to $140 million, signaling confidence in margin improvements and operational progress. Leverage concerns are easing as free cash flow turns positive, dilution slows, and interest expenses decline, aided by strong EOS imaging technology growth. Trading at just over 2x sales, Alphatec offers speculative appeal given robust growth, margin gains, and a significant discount to peer multiples. Read the full article on Seeking AlphaUppdatering av berättelse • Aug 05
ATEC: 2026 Revenue Mix Will Support Constructive Upside Case
Analysts have adjusted their price target on Alphatec Holdings from $24.00 to about $22.41. The change reflects updated assumptions around discount rate, revenue growth, profit margin, and future P/E estimates.
Uppdatering av berättelse • Jul 20
ATEC: 2026 Surgical Revenue Outlook Will Drive Future Upside Potential
Analysts have trimmed their price target for Alphatec Holdings from $17.33 to $16.00, citing updated fair value estimates, a slightly lower discount rate, and an adjusted future P/E assumption that reflects a more measured approach to valuation multiples. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, providing investors with updated expectations for the business.Uppdatering av berättelse • Jul 06
ATEC: 2026 Revenue Outlook Will Support Constructive Upside Case
Analysts have trimmed their price target for Alphatec Holdings to $24.00 from $28.00, reflecting updated assumptions for revenue growth, profit margins, the discount rate, and the future P/E multiple. What's in the News for Alphatec Holdings Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $882 million.
Uppdatering av berättelse • Jun 22
ATEC: Legal Overhang And 2026 Outlook Will Support Future Upside
Analysts have maintained their $11.00 price target for Alphatec Holdings, citing updated model assumptions that reflect slightly adjusted discount rates, revenue growth expectations, profit margins, and future P/E estimates. What’s in the News for Alphatec Holdings Schall Law Firm has begun an investigation into Alphatec Holdings, Inc.Uppdatering av berättelse • Jun 05
ATEC: New Bank Facility And 2026 Outlook Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $20.00 to $11.00, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Alphatec reported Q1 2026 total revenue of $192 million, with surgical revenue growth of 17% and total revenue growth of 14%, according to recent earnings coverage (source: Alphatec Reports Strong Q1 2026 Growth and Secures New Bank Facility).Uppdatering av berättelse • May 14
ATEC: 2026 Surgical Revenue Focus Will Support Future Upside Potential
Analysts have reduced their price target for Alphatec Holdings from about $24.62 to about $17.33 as they adjust assumptions for discount rate, revenue growth, profit margin, and future P/E in their models. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, targeting total revenue of about $882 million, with surgical revenue expected to grow 17% as part of that outlook (corporate guidance).Uppdatering av berättelse • Apr 29
ATEC: 2026 Revenue Guidance Will Drive Constructive Upside Case
Analysts have kept their $28.00 price target for Alphatec Holdings unchanged, noting that only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E offset one another in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, indicating no change to its previously communicated outlook.Uppdatering av berättelse • Apr 15
ATEC: 2026 Revenue Outlook Will Support Bullish Return Potential
Analysts have kept their $28.00 price target on Alphatec Holdings unchanged, citing updated assumptions that include a higher discount rate, stronger modeled revenue and profit margins, and a lower future P/E multiple that together balance out in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, maintaining its outlook for that period.Uppdatering av berättelse • Mar 31
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $22.00 to $20.00, citing updated assumptions for revenue growth, profit margins and future P/E that together point to a more measured long term outlook for the shares. What's in the News Reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% above full year 2025 revenue (Corporate Guidance).Uppdatering av berättelse • Mar 17
ATEC: 2026 Revenue Outlook And Spine Biologics Partnership Will Support Upside
Analysts have left their $28.00 price target for Alphatec Holdings unchanged, citing a slightly higher assumed discount rate, a moderated revenue growth outlook, stronger projected profit margins, and a lower future P/E as key factors supporting the steady valuation. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million.Uppdatering av berättelse • Mar 03
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside Potential
Analysts have adjusted their Alphatec Holdings target to $24.62, reflecting updated assumptions that combine slightly lower expected revenue growth with higher projected profit margins and a reduced future P/E multiple, while applying a somewhat higher discount rate. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% higher than full year 2025 revenue (company guidance).Uppdatering av berättelse • Feb 17
ATEC: 2026 Revenue Guidance And Spine Biologics Deal Will Drive Upside
Analysts have maintained their $28.00 price target for Alphatec Holdings, citing steady model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions as reasons to hold their prior valuation line. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately $890m for the year ended December 31, 2026 (Corporate Guidance).Uppdatering av berättelse • Feb 03
ATEC: Partnership And 2026 Revenue Outlook Will Reshape Spine Biologics Opportunity
Analysts have raised their fair value estimate for Alphatec Holdings from $23.00 to $28.00, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe better reflect the company’s current outlook. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of about $890 million compared to full year 2025 (Corporate Guidance).Uppdatering av berättelse • Jan 20
ATEC: Higher 2026 Revenue Outlook And New Partnership Will Support Upside
Analysts have lifted their price target on Alphatec Holdings from US$14.00 to US$22.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E as the key drivers of the change. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately US$890 million for the year.Analysartikel • Jan 06
Are Alphatec Holdings, Inc. (NASDAQ:ATEC) Investors Paying Above The Intrinsic Value?
Key Insights Alphatec Holdings' estimated fair value is US$17.32 based on 2 Stage Free Cash Flow to Equity Alphatec...Uppdatering av berättelse • Jan 06
ATEC: Higher 2025 Revenue Guidance Will Support A More Optimistic Outlook
Analysts have inched their price target for Alphatec Holdings higher to about $24.62 from $24.00, reflecting small tweaks to fair value estimates, discount rate assumptions, and a slightly higher future P/E multiple in their models. What's in the News Alphatec Holdings raised earnings guidance for the fiscal year ending December 31, 2025, indicating updated expectations for the business outlook.Uppdatering av berättelse • Dec 14
ATEC: Revenue Will Reach 760 Million As Outlook Remains Favorable
Analysts have modestly raised their price target on Alphatec Holdings by 0.25 dollars to 24.00 dollars, reflecting slightly higher long term valuation multiples despite only marginal tweaks to growth, margin and discount rate assumptions. What's in the News Alphatec Holdings raised its earnings guidance for fiscal 2025, now expecting total revenue to increase 24 percent to 760 million dollars, compared with the prior outlook of 742 million dollars (company guidance filing) Valuation Changes Fair Value Estimate has risen slightly to 24.00 dollars from 23.75 dollars, reflecting a modest uplift in long term valuation.Uppdatering av berättelse • Nov 29
ATEC: Revenue Will Reach $760 Million As Guidance Increases And Outlook Remains Steady
Analysts have maintained their fair value price target for Alphatec Holdings at $23.75, citing only minor adjustments to underlying financial assumptions along with a steady outlook for growth and profitability. What's in the News Alphatec Holdings raised its earnings guidance for the fiscal year ending December 31, 2025, reflecting increased confidence in the company's outlook (Key Developments).Uppdatering av berättelse • Nov 15
ATEC: Total Revenue Will Reach $760 Million Next Year
Narrative Update on Alphatec Holdings: Analyst Price Target Revision Analysts have increased their price target for Alphatec Holdings from $20.54 to $23.75. This change reflects revised financial assumptions and updated expectations for the company’s future performance.Uppdatering av berättelse • Nov 01
ATEC: Improved Margins And Revenue Projections Will Shape Future Performance
Analysts have raised their price target for Alphatec Holdings from $19.41 to $20.54 per share, citing improved profit margin forecasts and stronger projected revenue growth as key reasons for the increased valuation. What's in the News Alphatec Holdings, Inc.Analysartikel • Oct 05
Not Many Are Piling Into Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Yet
With a median price-to-sales (or "P/S") ratio of close to 2.8x in the Medical Equipment industry in the United States...Uppdatering av berättelse • Sep 20
Expanding Spine Care And Integrated Tech Will Drive Future Opportunities
The slight increase in Alphatec Holdings’ future P/E ratio reflects higher growth expectations, which has contributed to a modest rise in its consensus analyst price target from $18.95 to $19.41. What's in the News Raised full-year 2025 revenue guidance to $742 million, up 21% year-over-year, surpassing previous forecast of $734 million.Analysartikel • Jul 28
Are Investors Undervaluing Alphatec Holdings, Inc. (NASDAQ:ATEC) By 43%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Alphatec Holdings fair value estimate is US$19.10 Current...Analysartikel • Jul 09
Should You Investigate Alphatec Holdings, Inc. (NASDAQ:ATEC) At US$11.60?
While Alphatec Holdings, Inc. ( NASDAQ:ATEC ) might not have the largest market cap around , it led the NASDAQGS...Ny berättelse • May 27
Robotics And Minimally Invasive Techniques Will Expand Spine Care
Innovative spine solutions and expanding minimally invasive offerings position Alphatec for sustained revenue growth and margin expansion amid rising global spine care demand.Analysartikel • May 11
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 25% But Many Are Still Ignoring The Company
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have had a really impressive month, gaining 25% after a shaky period...Analysartikel • Apr 20
Alphatec Holdings (NASDAQ:ATEC) Is Making Moderate Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Mar 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
Shareholders of Alphatec Holdings, Inc. ( NASDAQ:ATEC ) will be pleased this week, given that the stock price is up 18...Analysartikel • Jan 18
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 31% But Many Are Still Ignoring The Company
Despite an already strong run, Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have been powering on, with a gain of 31...Analysartikel • Dec 19
Here's Why Alphatec Holdings (NASDAQ:ATEC) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Dec 03
Alphatec: A Big Recovery
Summary Alphatec, a medtech company focused on spine solutions, has faced investor concerns due to continued losses, cash burn, and increasing debt despite revenue growth. Shares plunged 40% after Q2 earnings, but have recovered following the release of the third quarter results following management's comments about positive cash flow in Q4. Management's optimistic outlook is further backed up by significant improvement in EBITDA seen in 2025. Despite the positive reaction, Alphatec still needs to prove its ability to reduce debt and avoid further dilution while executing its growth plans. Read the full article on Seeking AlphaAktieägarnas avkastning
| ATEC | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | 5.2% | 2.7% | 0.6% |
| 1Y | -37.6% | -11.6% | 20.1% |
Avkastning vs industri: ATEC presterade sämre än US Medical Equipment branschen som gav -11.6 % under det senaste året.
Avkastning vs Marknaden: ATEC presterade sämre än US marknaden som gav 20.1 % under det senaste året.
Prisvolatilitet
| ATEC volatility | |
|---|---|
| ATEC Average Weekly Movement | 7.6% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: ATEC har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: ATEC s veckovolatilitet ( 8% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1990 | 913 | Pat Miles | www.atecspine.com |
Alphatec Holdings, Inc, ett medicintekniskt företag, designar, utvecklar och förbättrar teknologier för kirurgisk behandling av ryggradssjukdomar i USA och internationellt. Företaget tillverkar och säljer implantat, instrument, avbildningsutrustning och reservdelar. Företaget erbjuder produktplattformen Alpha InformatiX, inklusive EOS bildsystem som ger avbildning av hela kroppen, SafeOp Neural InformatiX System som automatiserar övervakning av elektromyografi, somatosensoriskt framkallad potential och motoriskt framkallad potential, och Valence, ett intraoperativt system som integrerar navigering och robotteknik i ryggradsoperationer, samt Sigma Prone TransPsoas (PTP) Access och PTP Patient Positioning Systems.
Alphatec Holdings, Inc. Sammanfattning av grunderna
| ATEC grundläggande statistik | |
|---|---|
| Börsvärde | US$1.51b |
| Vinst(TTM) | -US$109.99m |
| Intäkter(TTM) | US$815.05m |
1.9x
P/S-förhållande-13.7x
P/E-förhållandeÄr ATEC övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ATEC resultaträkning (TTM) | |
|---|---|
| Intäkter | US$815.05m |
| Kostnad för intäkter | US$237.69m |
| Bruttovinst | US$577.37m |
| Övriga kostnader | US$687.36m |
| Intäkter | -US$109.99m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.71 |
| Bruttomarginal | 70.84% |
| Nettovinstmarginal | -13.50% |
| Skuld/egenkapitalförhållande | 4,991.8% |
Hur har ATEC utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/16 15:53 |
| Aktiekurs vid dagens slut | 2026/08/14 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Alphatec Holdings, Inc. bevakas av 27 analytiker. 14 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Matthew Miksic | Barclays |
| Vikramjeet Chopra | BMO Capital Markets Equity Research |
| Caitlin Cronin | Canaccord Genuity |